Abstract:Tuberculosis (TB) is the world’s second leading infectious killer. Cases of multidrug-resistant (MDR-TB) and extremely drug-resistant (XDR-TB) have increased globally. Therapeutic drug monitoring (TDM) remains a standard clinical technique for using plasma drug concentrations to determine dose. For TB patients, TDM provides objective information for the clinician to make informed dosing decisions. Some patients are slow to respond to treatment, and TDM can shorten the time to response and to treatment completion. Normal plasma concentration ranges for the TB drugs have been defined. For practical reasons, only one or two samples are collected post-dose. A 2-h post-dose sample approximates the peak serum drug concentration (Cmax) for most TB drugs. Adding a 6-h sample allows the clinician to distinguish between delayed absorption and malabsorption. TDM requires that samples are promptly centrifuged, and that the serum is promptly harvested and frozen. Isoniazid and ethionamide, in particular, are not stable in human serum at room temperature. Rifampicin is stable for more than 6 h under these conditions. Since our 2002 review, several papers regarding TB drug pharmacokinetics, pharmacodynamics, and TDM have been published. Thus, we have better information regarding the concentrations required for effective TB therapy. In vitro and animal model data clearly show concentration responses for most TB drugs. Recent studies emphasize the importance of rifamycins and pyrazinamide as sterilizing agents. A strong argument can be made for maximizing patient exposure to these drugs, short of toxicity. Further, the very concept behind ‘minimal inhibitory concentration’ (MIC) implies that one should achieve concentrations above the minimum in order to maximize response. Some, but not all clinical data are consistent with the utility of this approach. The low ends of the TB drug normal ranges set reasonable ‘floors’ above which plasma concentrations should be maintained. Patients with diabetes and those infected with HIV have a particular risk for poor drug absorption, and for drug–drug interactions. Published guidelines typically describe interactions between two drugs, whereas the clinical situation often is considerably more complex. Under ‘real–life’ circumstances, TDM often is the best available tool for sorting out these multi-drug interactions, and for providing the patient safe and adequate doses. Plasma concentrations cannot explain all of the variability in patient responses to TB treatment, and cannot guarantee patient outcomes. However, combined with clinical and bacteriological data, TDM can be a decisive tool, allowing clinicians to successfully treat even the most complicated TB patients.

Manometer extension for high pressure measurement: nuclear quadrupole resonance study of Cu2O with a modified Bridgman anvil cell up to 10 GPa.

A guide to therapeutic drug monitoring of β‐lactam antibiotics

Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections?

Antimicrobial therapeutic drug monitoring in critically ill adult patients – An international perspective on access, utilisation, and barriers

Therapeutic Drug Monitoring and Biomarkers; towards Better Dosing of Antimicrobial Therapy

The double-helix microscope super-resolves extended biological structures by localizing single blinking molecules in three dimensions with nanoscale precision.

Subject index Volume 5 (1990).

Direct growth of MnOOH nanorod arrays on a carbon cloth for high-performance non-enzymatic hydrogen peroxide sensing.

From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics

Research status on the therapeutic drug monitoring of β-lactam antibiotics in critically ill patients

Respiratory insufficiency in patients with severe head injury.

A nationwide utilization survey of therapeutic drug monitoring for five antibiotics in South Korea

Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#

A Review of Therapeutic Drug Monitoring of Beta-Lactams

Therapeutic Drug Monitoring in Anti-Infective Therapy: a Meta-analysis

A high performance liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of 10 drug compounds commonly used for antimicrobial therapy in plasma and serum of critically ill patients: Method optimization, validation, cross-validation and clinical application

Assessment of the practical impact of adjusting beta-lactam dosages based on therapeutic drug monitoring in critically ill adult patients: a systematic review and meta-analysis of randomized clinical trials and observational studies

Dose Individualisation of Antimicrobials from a Pharmacometric Standpoint: The Current Landscape

Salivary Therapeutic Drug Monitoring of Antimicrobial Therapy: Feasible or Futile?

Establishing and Extending the Use of Therapeutic Drug Monitoring in Neuropsychopharmacology

Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update